$SPRC SciSparc is a clinical-stage biotechnology c
Post# of 42189
(Total Views: 153)
Posted On: 01/03/2022 2:39:52 PM
$SPRC SciSparc is a clinical-stage biotechnology company developing cannabinoid-based therapeutics. The company's lead asset, SCI-110
(synthetic THC + palmitoylethanolamide (PEA)), is being developed for Tourette
syndrome (TS) (phase 2b) and Alzheimer's disease (AD) and agitation (phase 2a).
Additionally, SciSparc is developing SCI–210 (CBD + PEA) for status epilepticus
and autism spectrum disorder, and SCI-160 (a synthetic CB2 receptor agonist)
for pain. The company's achievements in 2021 included preparing to enter midstage studies with SCI-110, publishing key data underpinning the efficacy of its
programs, garnering additional IP protection, bolstering the balance sheet with
successful capital markets activities, and uplisting to the Nasdaq exchange.
(synthetic THC + palmitoylethanolamide (PEA)), is being developed for Tourette
syndrome (TS) (phase 2b) and Alzheimer's disease (AD) and agitation (phase 2a).
Additionally, SciSparc is developing SCI–210 (CBD + PEA) for status epilepticus
and autism spectrum disorder, and SCI-160 (a synthetic CB2 receptor agonist)
for pain. The company's achievements in 2021 included preparing to enter midstage studies with SCI-110, publishing key data underpinning the efficacy of its
programs, garnering additional IP protection, bolstering the balance sheet with
successful capital markets activities, and uplisting to the Nasdaq exchange.
(0)
(0)Scroll down for more posts ▼